Adalimumab (HUMIRA®) is effective in treating patients with rheumatoid arthritis who previously failed infliximab treatment

被引：0
|
作者：
Van der Biji, AE
Breedveld, FC
Antoni, CE
Kalden, JR
Kary, S
Burmester, GR
Unnebrink, K
Kupper, H
机构：
[1] Leiden Univ, Med Ctr, Leiden, Netherlands
[2] Univ Erlangen Nurnberg, Erlangen, Germany
[3] Charite Humbold Univ, Berlin, Germany
[4] Abbott GmbH Co KG, Ludwigshafen, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2005年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：428 / +
页数：2
相关论文
共 50 条
  • [21] THE EFFICACY OF ETANERCEPT AND ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAVE FAILED TREATMENT WITH DMARDS: A META-ANALYSIS
    Reynolds, A. V.
    Bacon, P. A.
    RHEUMATOLOGY, 2003, 42 : 91 - 91
  • [22] Adalimumab for treating rheumatoid arthritis
    Navarro-Sarabia, Federico
    Ariza-Ariza, Rafael
    Hernandez-Cruz, Blanca
    Villanueva, Isidro
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (06) : 1075 - 1081
  • [23] The efficacy of etanercept and infliximab in patients with rheumatoid arthritis who have failed treatment with DMARDs: A meta-analysis.
    Bacon, PA
    Reynolds, AV
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S332 - S333
  • [24] Adalimumab for treating rheumatoid arthritis
    Navarro-Sarabia, F
    Ariza-Ariza, R
    Hernandez-Cruz, B
    Villanueva, I
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (03):
  • [25] THE IMPACT OF CHANGES IN ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB DOSES ON THE COSTS OF TREATING RHEUMATOID ARTHRITIS
    Lawson, R. W.
    Heatley, R. M.
    Johnson, K., I
    Khandker, R. K.
    Singh, A.
    VALUE IN HEALTH, 2010, 13 (07) : A308 - A308
  • [26] The cost-utility of adalimumab (Humira) in patients with rheumatoid arthritis (RA) in Denmark
    Aagren, M.
    Davies, A.
    Pang, F.
    Winding, B.
    VALUE IN HEALTH, 2006, 9 (06) : A223 - A223
  • [27] THE COST-EFFECTIVENESS OF ADALIMUMAB (HUMIRA™) IN PATIENTS WITH RHEUMATOID ARTHRITIS: A UK ANALYSIS
    Bansback, N.
    Brennan, A.
    Sengupta, N.
    Pang, F.
    RHEUMATOLOGY, 2004, 43 : 77 - 77
  • [28] The cost-effectiveness of adalimumab (HUMIRA®) in patients with rheumatoid arthritis (RA) in Denmark
    Aagren, M.
    Davies, A.
    Winding, B.
    Cifaldi, M.
    Pang, F.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2006, 35 : 15 - 15
  • [29] Safety and efficacy of adalimumab (Humira®) in patients with rheumatoid arthritis in Germany:: React study
    Burmester, GR
    Alten, R
    Tony, H
    Liman, W
    Gromnica-Ihle, E
    Stierle, HE
    Zeidler, H
    Von Hinüber, U
    Kellner, H
    Häntzschel, H
    Lemma, E
    Zeise, E
    Kupper, H
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 266 - 266
  • [30] Adalimumab (Humira®) is effective and safe in treating rheumatoid arthritis (RA) in real-life clinical practice:: Final summary of the 6610 patients in the react study
    Burmester, G. R.
    Saez, I. Monteaguclo
    Fardellone, P.
    Montecucco, C. M.
    Nash, P.
    Katy, S.
    Kupper, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 181 - 181
12345